Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com

Stock Price vs Company Growth
1d
2.5%
1w
4.1%
1m
5.2%
3m
16.8%
6m
71.9%
1y
71.8%
5y
35.3%
10y
19.2%
all
18.6%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 303 2.5%
240
351
Company Overview

Sales
3,172 Cr
Growth: 15.1%
Profit after Tax
517 Cr
Growth: 23.7%
Mid Cap
13,738 Cr
P/E: 26.6x
Industry P/E: 32.5x
Fundamentals

Sales (Cr) ₹ 3,172
Growth 15.1%
EBITDA 22.5%
P/S 4.3x
Dividend 0.4%
P/E 26.6x
Book Value ₹ 70.2
PEG Ratio 1.8x
ROE 17.9%
P/B 4.4x
Shareholding Pattern

Institutions
Promoters
Mark Saldanha
48.25 %
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Increase    Decrease    No change
Company Profile Detailed

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.
Investors (52)
Followers (8)